Forbion raises €2.3 billion across two new funds

Forbion raised €2.3 billion ($2.6 billion), its largest fundraise to date and one of the largest global life sciences VC raises in the past five years, substantially exceeding its target. The capital brings assets under management to approximately €7.5 billion and gives its two newest funds capacity to finance about 30 portfolio companies; initial investments have already been completed. The raise signals strong investor demand for Forbion amid a market-wide shortage of capital.

Analysis

For public equities, this is a capital-supply signal, not an earnings catalyst. If Forbion deploys successfully, better-funded European and North American biotechs could extend runway and reach clinical milestones without accepting distressed terms. The second-order effect is tougher competition for assets and talent, potentially lifting entry valuations and making later-stage returns more dependent on clinical differentiation and exit conditions. CROs and specialist service providers may benefit only if funded companies convert capital into trial starts; deployment pace is the key missing evidence.

Eli Lilly’s participation offers potential sourcing and partnership access, but the release gives no investment amount, rights, or deal pipeline. Treat it as strategic optionality, not a material LLY valuation input. The raise could also intensify competition with other biotech investors and strategic acquirers for promising programs; it does not establish that IPO or M&A markets can absorb future exits.

Near term, likely limited read-through to listed names. Over 1–3 months, track disclosed portfolio investments, clinical-trial starts, and whether other specialist funds follow with closes. Over 6–18 months, the test is whether financed companies produce clinical validation and realizable exits. The contrarian risk is that abundant capital supports higher private marks and delays repricing rather than creating durable value. No directional public-equity trade is justified on this announcement alone.

Key Decisions for Investors

• Keep LLY exposure unchanged on this news: verify the size and terms of its commitment and any resulting collaboration before assigning financial value; the announcement alone does not establish material earnings exposure.
• Treat European biotech financing conditions as a watch item, not a buy signal. Track new fund closes, disclosed investments, and portfolio trial starts over the next 1–3 months for evidence that capital is reaching operating companies.
• Avoid chasing private-biotech read-throughs into listed peers or CROs until deployment translates into funded trials and revenue visibility; fundraising capacity is not equivalent to near-term spending.
• Falsify the constructive capital-supply thesis if deployment stalls, portfolio companies continue to require distressed financing, or clinical and exit milestones fail to follow over the next 6–18 months.